tbuckley/cabot-search huggingface dataset:
894P Utility of histopathological revision in the management of gastro-entero-pancreatic neuroendocrine neoplasia
Authors: L. Magi, M. Marasco, E. Rogges, E. Dell'Unto, M. Rinzivillo, E. Pilozzi, B. Annibale, F. Panzuto
Journal: Annals of Oncology (2022)
850P A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma
Authors: A.M. Taylor, C. Galea, A.H.R. Varey, K.F. Shannon, S. Ch'ng, R.P.M. Saw, T.E. Pennington, J. Stretch, A.J. Spillane, A.C.J. van Akkooi, I. Pires da Silva, M.S. Carlino, R.A. Scolyer, G.V. Long, S.N. Lo, A.M. Menzies
Journal: Annals of Oncology (2022)
676P ATHENA: A multicenter phase II of atezolizumab (A) and bevacizumab (B) in patients (pts) with recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M HNSCC) - The HPV-negative cohort
Authors: J. Fayette, E.B. Saada, A. DeMontfort, A. Karabajakian, E.M. Neidhardt, C. Borel, M. Burgy, H. Carinato, J-P. Delord, S. Betrian, P. Toussaint, None T. Chatellier, None T. lharidon, G. Garin, None M. Bernardin, L. Jaouen, I. Sondarjee, D. Perol, J-Y. Blay
Journal: Annals of Oncology (2022)
831P Outcomes of immune checkpoint inhibitors in patients with metastatic uveal melanoma treated with tebentafusp
Authors: E.C. Koch, D.P. Arteaga Ceballos, M. Vilbert, K. Lajkosz, T. Pimentel Muniz, I. Hirsch, M.F. Silva Almeida Ribeiro, L. Mantle, M. Anczurowski, D. Hogg, S. Saibil, A. Spreafico, H. Krema, M.O. Butler
Journal: Annals of Oncology (2022)
572P High concordance of different molecular assays in the determination of HRD associated GIS in high grade epithelial ovarian cancer
Authors: W. Weichert, S. Bartels, I. Braicu, Y. Christinat, M. Demes, V. Endris, S. Herold, L.C. Heukamp, M. Hummel, U. Lehmann, S. Merkelbach-Bruse, N. Pfarr, R. Rad, J. Sehouli, J. Siemanowski, A. Stenzinger, K. von Schwarzenberg, C. Vollbrecht, P.J. Wild, D. Zocholl
Journal: Annals of Oncology (2022)
492TiP A phase I study of synthetic lethal, IDE397 (MAT2A inhibitor) as a monotherapy and in combination with chemotherapy in advanced solid tumors harboring MTAP deletion
Authors: M.L. Johnson, J. Rodon, R. Aljumaily, M. Villalona-Calero, E. Borazanci, M. Pishvaian, A. Turk, R.D. Carvajal, C. Mantia, G. Giaccone, Z. Mounir, A. Patel, M. Maurer, C. Neilan, D. Rajendran, U. Ganesan, J. Hinkle, A.W. Tolcher
Journal: Annals of Oncology (2022)
815P A single-arm, phase II clinical study of imatinib mesylate/toripalimab combo in patients (pts) with advanced melanoma harboring c-Kit mutation or amplification
Authors: L. Si, Z. Qi, J. Dai, X. Bai, L. Mao, C. Li, X. Wei, C-L. Cui, Z. Chi, X. Sheng, Y. Kong, T. Bixia, L. Zhou, B. Lian, X. Wang, R. Duan, J. Guo
Journal: Annals of Oncology (2022)
948TiP Efficacy and safety of almonertinib in the adjuvant treatment of resectable stage I non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-sensitizing mutations in solid and/or micropapillary components
Authors: B. Han, V. Fang, F. Yao, P. Song, D. Yue, Y. Qi, B. Zhang, W. Zhang, Y. Zhang, L. Tan
Journal: Annals of Oncology (2022)
434P Cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma: A single center experience
Authors: M. Valery, B. Cervantes, C. Smolenschi, V. Boige, A. Boileve, D. Malka, A. Hollebecque, M.P. Ducreux
Journal: Annals of Oncology (2022)
407P Cross-sectoral colorectal cancer care in Germany in the context of the COVID-19 pandemic and scarcity of resources
Authors: C. Lugnier, T. Birkner, S. Sommerlatte, H. Hense, A-L. Kraeft, J. Christmann, S. Foerster, O. Schoffer, A. Stein, R. Reichelt, W. Knauf, None C. Biermann, O. Overheu, A. Tannapfel, J. Schildmann, A. Reinacher-Schick, J. Schmitt
Journal: Annals of Oncology (2022)
CN36 Informal caregivers’ contributions to self-care for patients treated with oral anticancer agents: A qualitative study
Authors: S. Ucciero, F. Sollazzo, M. Di Nitto, A. Durante, F. Lacarbonara, V. Biagioli, F. Torino, R. Alvaro, E. Vellone
Journal: Annals of Oncology (2022)
1005P Indirect treatment comparisons of relative efficacy for aumolertinib vs osimertinib in EGFR-positive non-small cell lung cancer (NSCLC)
Authors: S. Popat, S. Stergiopoulos, S. King, M. Curtis, A. Dillon, R. Akehurst, D. Lee, F. Guelfucci, A. Ngami, F. Bianic, Y. Li, S. Ali, V. Miller
Journal: Annals of Oncology (2022)
963P Clinical research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-world evidence of NSCLC patients treated with radiochemotherapy in Germany – AIO-TRK-0315
Authors: W.E.E. Eberhardt, B. Passlick, M. Stuschke, A. Groeschel, P. Christopoulos, M. Reck, P. Ludwig, A. Hipper, M. Chiabudini, L. Spring, M. Jänicke, A. Andres-Pons, D.C. Christoph, C. Bernhardt, M. Reiser, M. Sebastian, F. Griesinger, M. Thomas
Journal: Annals of Oncology (2022)
929MO Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small cell lung cancer (NSCLC): Pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study
Authors: J. Spicer, T. Cascone, G. Kar, Y. Zheng, J. Blando, T.H. Tan, M. Cheng, R. Mager, O. Hamid, Y. Soo-Hoo, P.M. Forde, W. Weder, M.R. Garcia Campelo, I. Grenga, R. Kumar, L. McGrath
Journal: Annals of Oncology (2022)
474P Evaluation of gelatinase-responsive copolymeric nanoparticles targeting PD-1 and TGF-β pathways for treating immune-resistant tumor
Authors: Y. Yen, A. Chen, Z. Zhang, Q. Wang, C. Li, Z. Wei, X. Li, X. Wang, F. Meng, J. Shao, None L. Yu, B. Liu, R. Li
Journal: Annals of Oncology (2022)
742P First-in-human phase I study of INCAGN02385, a LAG-3 monoclonal antibody antagonist in patients with advanced malignancies
Authors: J.D. Powderly, O. Hamid, M.E. Gutierrez, A.S. Balmanoukian, J. Janik, P. Hoyle, Z. Dong, W. Wei, X. Chen, N. Bourayou, L. Horn
Journal: Annals of Oncology (2022)
380P Tumour naïve circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial
Authors: D. Day, A. Starus, A. Lamik, O. Sieber, S. Begbie, A. Bonaventura, S. Rai, N. Karanth, C.R. Underhill, L.M. Nott, G. van Hazel, T. van Hagen, M. Wong, A. Saqib, M. Eastgate, R. Srivastav, J. Chia, H.C. Toh, F. Jones, E. Segelov
Journal: Annals of Oncology (2022)
453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study
Authors: T. Doi, M. Patel, G.S. Falchook, T. Koyama, C.F. Friedman, S. Piha-Paul, M.E. Gutierrez, R. Abdul-Karim, M. Awad, D.R. Adkins, S. Takahashi, S. Kadowaki, B. Cheng, N. Ikeda, A. Laadem, N. Yoshizuka, M. Qian, O. Dosunmu, H-T. Arkenau, M.L. Johnson
Journal: Annals of Oncology (2022)
481P A phase I first-in-human study of XL092 in patients (pts) with locally advanced or metastatic solid tumors: Results from dose-escalation of XL092 alone and in combination with atezolizumab
Authors: M.R. Sharma, V. Subbiah, G. Shapiro, S.K. Pal, N. Agarwal, K. Wentzel, B. Fang, N. Zhang, M. Schwickart, Z. Wang, D. Curran, A. Patnaik
Journal: Annals of Oncology (2022)
602P Using scenarios to explain survival times – attitudes of women with gynaecological cancer
Authors: K. Lindemann, H. Liland, M. Paus Reinertsen, A. Jabri Haug, J. Deu Martinez, M.R. Stockler, G. Aune, B.E. Kiely, I. Vistad, T. Paulsen
Journal: Annals of Oncology (2022)
403P First-line anti-EGFR therapy, patient characteristics and survival: Results from South Australian (SA) metastatic colorectal registry (mCRCR)
Authors: T.J. Price, C.S. Karapetis, B. Geerinckx, A.C. Roy, None D. Roder, R. Padbury, A. Townsend
Journal: Annals of Oncology (2022)
968TiP A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial)
Authors: S.Y. Lee, J.E. Lee, C-M. Choi, I-J. Oh, K. Lee, T. Jang, S.H. Lee, E.Y. Kim, D.W. Park, S.H. Park
Journal: Annals of Oncology (2022)
1008P Resistance mechanisms to lorlatinib or crizotinib in treatment-naive patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC)
Authors: E. Felip, J-F. Martini, J. Mazieres, D-W. Kim, D. Shepard, A. Polli, G. Liu, F. de Marinis, F. Toffalorio, Y. Goto, B. Solomon
Journal: Annals of Oncology (2022)
1000P Common and uncommon mutations in NSCLC: Differences in response to treatment with tyrosine kinase inhibitors: A single-center retrospective analysis
Authors: C. Sciortino, B. Bovolenta, G.A. Marrocco, G. Martino, A. Neri, M. Nucci, L. Pappalardo, M.G. Polito, V. Viglialoro, E. Cortesi, S. Caponnetto
Journal: Annals of Oncology (2022)
532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
Authors: K.N. Moore, A.M. Oza, N. Colombo, A. Oaknin, G. Scambia, D. Lorusso, S. Banerjee, C. Murphy, J. Konner, P. Lim, M. Prasad-Hayes, B.J. Monk, J. Wang, M.J. Birrer, I.B. Vergote
Journal: Annals of Oncology (2022)
490P Safety and efficacy of tusamitamab ravtansine in patients with colorectal or gastric cancer expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
Authors: A. Italiano, A. Gazzah, J. Tabernero, Y-K. Kang, E. Calvo, M. Provencio Pulla, Y-J. Bang, F. Barlesi, P.L. Bedard, J.O. Park, J-S. Kim, M. Chadjaa, S. Yoruk, J-P. Delord
Journal: Annals of Oncology (2022)
999P JIN-A02, a fourth-generation, highly effective tyrosine kinase inhibitor with intracranial activity, targeting EGFR C797S mutations in NSCLC
Authors: M.R. Yun, M.R. Yu, K.B. Duggirala, K. Lee, S.M. Lim, A. Jo, E. Seah, C. Kim, B.C. Cho
Journal: Annals of Oncology (2022)
487P Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies
Authors: C.E. Heilig, M-V. Teleanu, I.A. Bhatti, S. Richter, J.T. Siveke, S. Wagner, H-G. Kopp, T. Kindler, L. Illert, A. Golf, K. Dormann, A. Benner, H. Süsse, A. Freitag, C. Von Kalle, H. Glimm, D. Hübschmann, S. Fröhling, R.F. Schlenk
Journal: Annals of Oncology (2022)
347P Prognostic impact of signet ring cell proportion in colorectal cancer patients with peritoneal metastases
Authors: V. Kepenekian, A. Kefleyesus, G. Petrides, S. Barat, I. Bonnefoy, S. Valle, J. Peron, N. Alzahrani, O. Glehen, D. Morris
Journal: Annals of Oncology (2022)
870P Systemic levels of the soluble co-inhibitory and co-stimulatory immune checkpoint molecules in basal cell carcinoma
Authors: B.L. Rapoport, N. Malinga, S. Siwele, H. Steel, L. Kwofie, P. Meyer, T. Smit, R. Anderson, M. Kgokolo
Journal: Annals of Oncology (2022)
782TiP Reduced frequency immune checkpoint inhibition in cancers (REFINE): A multi-arm phase II trial testing reduced intensity immunotherapy in different cancers
Authors: S. Merrick, M. Nankivell, T. Griffiths, W. Hudson, C.S. Clarke, G. Bray, S. Forcat, M. Campos, H. Bryant, M. Quartagno, R. Langley, L.M. Pickering, N.S. Vasudev, D. Gilbert
Journal: Annals of Oncology (2022)
829P A proof of concept study of sequential treatment with the HDAC inhibitor vorinostat plus BRAF and MEK inhibitors in BRAFV600 mutated melanoma
Authors: A. Embaby, S.C.F.A. Huijberts, L. Wang, R. Leite de Oliveira, H. Rosing, B. Nuijen, C.U. Blank, H.V. van Thienen, A. Meerveld-Eggink, J.B.A.G. Haanen, J.H. Beijnen, A. Huitema, R. Bernards, J.H.M. Schellens, S. Wilgenhof
Journal: Annals of Oncology (2022)
342P A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients
Authors: A. Rodriguez-Ariza, M.A. Gomez España, M.E. Elez Fernandez, M.C. Gravalos Castro, P. García Alfonso, F. Losa, I.C. Ales Diaz, B. Grana Suarez, I. Gallego, M.V. García-Ortiz, E. Polo Marques, M. Salgado Fernandez, F. Rivera Herrero, M.J. Safont Aguileria, M.A. Salud Salvia, A. Ruiz-Casado, J. Tabernero, M.C. Riesco Martinez, M. Toledano-Fonseca, E. Ara Aguilar
Journal: Annals of Oncology (2022)
TCT-604 Outcomes in Single vs Double Perclose ProGlide Device Technique During Transfemoral Transcatheter Aortic Valve Implantation: Meta-Analysis
Authors: Gaurav Aggarwal, Arun Kanmantha Reddy, Sakshi Bansal, Saurabh Aggarwal, Abhishek Thandra, Michael Delcore
Journal: Journal of the American College of Cardiology (2022)
116P Any regression of tumor (ART) as an intermediate endpoint in patients (pts) treated with immune checkpoint inhibitors (ICI): A pan-cancer analysis
Authors: T. El Zarif, G. Pond, A. Nassar, E. Adib, D. Freeman, J. Thomas, U. Kalluri, A. Matar, E. Kelly, C. Curran, A. Kadamkulam Syriac, H. McClure, M. Davidsohn, C. Labaki, R.M. Saliby, C.S. Hobeika, P.V. Nuzzo, J.E. Berchuck, T.K. Choueiri, G.P. Sonpavde
Journal: Annals of Oncology (2022)
909P A multi-cancer early detection model based on liquid biopsy of multi-omics biomarkers: A proof of concept study (PROMISE study)
Authors: Q. Gao, C. Wang, X. Yang, S. Fang, Y. Zhang, G. Wang, F. Liu, X. Wen, J. Zhao, G. Zhou, B. Li, S. Cai, Z. Zhang, J. Fan
Journal: Annals of Oncology (2022)
CN12 Impact of diet on immune checkpoint blockade: Nurse-directed dietary intervention
Authors: J. Malo, M. Benlaïfaoui, K. Diop, M. Messaoudene, W. Belkaid, A. Elkrief, N. Blais, M. Tehfe, M. Florescu, A. Al-Saleh, A. Leblanc, V. Marcil, B. Routy, C. Richard
Journal: Annals of Oncology (2022)
560P Neoadjuvant camrelizumab plus chemotherapy in patients with locally advanced cervical cancer (NACI): A prospective, single-arm, phase II trial
Authors: J. Chen, K. Li, Y. Han, Y. Shen, Y. Wang, K. Song, X. Chen, B. Xia, D. Zou, Y. Wang, D. Ma
Journal: Annals of Oncology (2022)
289MO Next-generation sequencing (NGS) for identifying actionable molecular alterations in newly diagnosed and recurrent IDHwt-glioblastoma (GBM) patients: A large mono institutional experience
Authors: M. Padovan, M. Maccari, A. Bosio, S. Vizzaccaro, I. Cestonaro, M. Corrà, M. Caccese, G. Cerretti, None M. Fassan, V. Zagonel, G. Lombardi
Journal: Annals of Oncology (2022)
741P Phase I results demonstrate highly differentiated safety and PK profile of ADG126, a masked anti-CTLA-4 SAFEbody in patients with advanced solid tumors
Authors: G. Richardson, A.W. Tolcher, M. Morris, P. de Souza, A. Hamid, X.K. She, L. Zhu, S. Zheng, G. Liu, Y. Li, F. Du, S. Fischkoff, H. Gong, J. Zha, P.P. Luo
Journal: Annals of Oncology (2022)
CN18 Challenges in genetic counseling in hereditary cancer syndromes in Mexican population and prevention clinic experience
Authors: C.H. Burciaga-Flores, M.L. Garza-Rodriguez, M.F. Noriega Iriondo, O.A. Zayas, F. Alcorta-Nuñez, J.F. Gonzalez Guerrero, A. Alcorta-Garza, D. Hernandez Barajas, O. Vidal-Gutiérrez, D.C. Pérez-Ibave
Journal: Annals of Oncology (2022)
675P Patterns of radiological responses to anti-PD1 in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in TOPNIVO (T) study
Authors: C. Even, A. Bernard-Tessier, M. Texier, O. Ben Said, M. Iacob, A. Daste, J. Fayette, S. Zanetta, G. Lefebvre, M. Vinches, A.C. Johnson, L. Bozec Le Moal, E.B. Saada, I. Jallut, F. Garic, L. Monard, J. Bourhis, J. Guigay, A. Auperin, S. Ammari
Journal: Annals of Oncology (2022)
761P Tumor infiltrating lymphocytes expressing membrane-bound IL-2 and IL-12 exhibit enhanced proliferation, function, and persistence without requiring exogenous IL-2 support
Authors: R.J. Silver, M. Silva, M.F. Maloney, A.A. Brate, N. El-Sayes, E.I. Ozay, D. Parwanda, C. Bartlett, A. Sharei, S.M. Loughhead, J. Gilbert, D.T. Bridgen
Journal: Annals of Oncology (2022)
843P Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma
Authors: T. Sato, A.P. Ikeguchi, P. Nathan, R.D. Carvajal, A.N. Shoushtari, T.F. Gajewski, J.C. Hassel, M. Rioth, S. Leyvraz, G.A. Daniels, L. Hernandez-Aya, D.B. Johnson, K. Kim, J.M. Piulats Rodriguez, C.L. Cowey, S. Lockwood, L. Collins, O. Karakuzu, J.J. Sacco, M.O. Butler
Journal: Annals of Oncology (2022)
378P Liquid biopsy detects early molecular response and predicts benefit to first-line chemotherapy plus cetuximab in metastatic colorectal cancer: PLATFORM-B study
Authors: J. Vidal Barrull, M. Nieva Munoz, C. Fernandez-Rodriguez, P. García Alfonso, D. Paez, V. Alonso-Orduna, M.T. Cano Osuna, C. Santos Vivas, G. Duran, M.E. Elez Fernandez, J.L. Manzano Mozo, R. Garcia-Carbonero, E. Pineda, J. Sastre Varela, F. Rivera Herrero, B. Bellosillo Paricio, J. Tabernero, E. Aranda Aguilar, R. Salazar, C. Montagut Viladot
Journal: Annals of Oncology (2022)
315O Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort
Authors: Y. Kuboki, R. Yaeger, M.G. Fakih, J.H. Strickler, T. Masuishi, E.J. Kim, C.M. Bestvina, C.J. Langer, J.C. Krauss, S. Puri, P. Cardona, E. Chan, Q. Tran, D.S. Hong
Journal: Annals of Oncology (2022)
153P HER2DX risk-score in the context of the PREDICT online-tool: A correlative analysis of the Short-HER clinical trial in early-stage HER2-positive (HER2+) breast cancer (BC)
Authors: P.F. Conte, L. Pare Brunet, F. Brasó-Maristany, N. Chic, O. Martinez Saez, M.V. Dieci, M. Marin, V. Guarneri, A. Vivancos, P. Villagrasa Gonzalez, J. Parker, C.M. Perou, A. Prat
Journal: Annals of Oncology (2022)
1056P KRAS and LKB1 mutation conferring prognostic and predictive role on liquid biopsy in advanced NSCLC
Authors: A. Bottiglieri, L. Provenzano, A. Spagnoletti, L. Mazzeo, M. Ganzinelli, G. Lo Russo, R. Ferrara, C. Proto, A. De Toma, M. Brambilla, M. Occhipinti, S. Manglaviti, T. Beninato, M.C. Garassino, J. Filosa, G. Di Guida, F.G.M. De Braud, G. Viscardi, C.M. Della Corte, A. Prelaj
Journal: Annals of Oncology (2022)
122P Can circulating PD-1, PD-L1, pan-BTN3As, BTN3A1, BTN2A1 and BTLA levels enhance prognostic power of serum CA125 in patients with advanced high-grade serous ovarian cancer?
Authors: L.R. Corsini, D. Fanale, C. Brando, S. Cutaia, M.C. Di Donna, U. Randazzo, L. Magrin, C. Filorizzo, V. Gurrera, A. Fiorino, E. Pedone, M. Di Piazza, A. Dimino, R. Scalia, R. Romano, T.D. Bazan Russo, V. Chiantera, A. Russo, V. Bazan, J.L. Iovanna
Journal: Annals of Oncology (2022)
287MO A phase 0 ‘trigger’ trial of pamiparib in newly diagnosed and recurrent glioblastoma patients
Authors: N. Sanai, S.N. Mehta, Y-W. Chang, J. Jiang, J. Molloy, C. Pennington-Krygier, J. Harmon, A. Hong, J. Wanebo, W. Kennedy, M. Garcia, I. Barani, W. Yoo, A. Tovmasyan, A-C. Tien, J. Li
Journal: Annals of Oncology (2022)
821P Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma
Authors: M. Schlaak, R. Dummer, J.M. Kirkwood, A. Joshua, M. Milhem, L. Gastaud, C. Mauch, M.L. Yushak, S. Lockwood, C. Hayes, A.N. Shoushtari
Journal: Annals of Oncology (2022)
TCT-605 Single Arterial Access for Transfemoral Transcatheter Aortic Valve Implantation With the ACURATE neo Self-Expanding Aortic Bioprosthesis
Authors: Rodrigo Bagur, Michael Chu, Patrick Teefy, Matthew Valdis, Jill Gelinas, Gloria Chaumont, Pantelis Diamantouros
Journal: Journal of the American College of Cardiology (2022)
TCT-127 Medical Therapy Versus Early Revascularization in Diabetics With Chronic Total Occlusion of Coronary Arteries: A Meta-analysis and Systematic Review
Authors: Abdul Wazir, Muhammad Khan, Farhad Sami, F.N.U. Salman, Furqan Khattak, Jay Shah, Madeeha Shafqat, Amir Khan, Abid Adil, Maryam Sana, Muhammad Ahsan, Ghulam Mujtaba Ghumman, Hemindermeet Singh, Mohammed Taleb, Syed Ali
Journal: Journal of the American College of Cardiology (2022)
90P Infrared molecular fingerprinting: A new in vitro diagnostic platform technology for cancer detection in blood-based liquid biopsies
Authors: M. Zigman, M. Huber, K. Kepesidis, L. Voronina, F. Fleischmann, E. Fill, J. Hermann, I. Koch, T. Kolben, G.B. Schulz, F. Jokisch, N. Reinmuth, W. Gesierich, J. Behr, N. Harbeck, M. Reiser, C.G. Stief, F. Krausz
Journal: Annals of Oncology (2022)
136MO Differential benefit of low-dose cyclophosphamide and methotrexate maintenance chemotherapy among TNBC subtypes in the context of the IBCSG 22-00 study
Authors: A. Joaquin Garcia, M. Rediti, D. Venet, S. Majjaj, R. Kammler, M.A. Colleoni, S. Loi, G. Viale, M.M. Regan, F. Rothé, C. Sotiriou
Journal: Annals of Oncology (2022)
280O Pharmacokinetics and pharmacodynamics of paxalisib in newly diagnosed glioblastoma patients with unmethylated MGMT promoter status: Final phase II study results
Authors: P. Wen, J.F. de Groot, J. Battiste, S. Goldlust, D. Damek, B. Ellingson, J. Garner, J. Friend, J. Simpson, A. Olivero, T. Cloughesy
Journal: Annals of Oncology (2022)
699P The molecular and immune landscape of recurrent head and neck squamous cell carcinoma (HNSCC) in patients undergoing definitive therapy
Authors: A. Alloghbi, J.E. McGrath, I. Aijazuddin, T. Wise-Draper, J. Leddon, P. Walker, M. Oberley, A. Sukari
Journal: Annals of Oncology (2022)
469P A phase I study of palbociclib in combination with cisplatin or carboplatin in advanced solid malignancies
Authors: O.B. Alese, M.A. Bilen, E. Hitron, C. Lewis, H.H. Collins, S. Scott, B. Carthon, Y. Cao, J.M. Switchenko, R.D. Harvey, T.K. Owonikoko
Journal: Annals of Oncology (2022)
385P The prognostic value of circulating in blood tumor DNA after surgery in I-III stages colorectal cancer
Authors: E. Polyanskaya, M. Fedyanin, B. Uliana, A. Kechin, E. Moroz, E. Khrapov, I. Oskorobin, S. Darya, V. Aliev, A. Tryakin, M. Filipenko, S. Tjulandin
Journal: Annals of Oncology (2022)
TCT-602 Comparison of Bleeding and Vascular Complications With Single vs Double ProGlide Vascular Closure After Transcatheter Aortic Valve Replacement
Authors: Nathan Frogge, Linda Schulte, Tinna Kosoko-Thoroddsen, Marc Sintek, Spencer Melby, John Lasala, Harold Roberts, Alan Zajarias
Journal: Journal of the American College of Cardiology (2022)
706TiP Phase III study assessing the “best of” radiotherapy compared to the “best of” surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0-N1 oropharyngeal, supraglottic carcinoma and with T1, N0 hypopharyngeal carcinoma
Authors: C. Simon, C. Fortpied Lefevre, A-S. Govaerts, T. Raveloarivahy, J. Bourhis, M. Evans, J.P. Klussmann, C.R. Leemans, K.D. Hunter, S. Singer, S. Nuyts, E. Willemse, M. Ansarin, G. Spriano, W. Golusinski, R. Giger, A. Boehm, F. Lopez, V. Grégoire
Journal: Annals of Oncology (2022)
94P Performance validation of an artificial intelligence-powered programmed death-ligand 1 (PD-L1) combined positive score analyzer in urothelial cancer
Authors: J.H. Park, S.I. Cho, K.S. Lee, E. Choi, W. Jung, S. Kim, G. Park, S. Song, C. Kang, M. Ma, D. Yoo, K. Paeng, C-Y. Ock
Journal: Annals of Oncology (2022)
614P Tolerance and preliminary efficacy of intraperitoneal (IP) nivolumab after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients (pts) with advanced ovarian carcinoma: A phase I study with expansion cohort (ICONIC)
Authors: P. Corbaux, B. You, V. Kepenekian, N. Bakrin, A. Gelot, D. Dayde, C. Sajous, M. Lamuraglia, J. Peron, O. Glehen, G. Freyer
Journal: Annals of Oncology (2022)
695P Effectiveness and quality-of-life (QoL) data from real-world study (ProNiHN) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) treated with nivolumab (nivo) in France
Authors: C. Le Tourneau, S. Salas, Y. Pointreau, P. Ceruse, E. Babin, V. Rondeau, J. Guigay, M. Rotarski, M. Chehimi, C. Toullec, G. Marie, C. Sire, A. Darut Jouve, A. Theron, B. Calderon, A. Houessinon, F-E. Cotté, M. Lavignon, C. Even, J. Fayette
Journal: Annals of Oncology (2022)
578P Genotype-phenotype correlation in diverse pathogenic variants in BRCA genes in patients with ovarian cancer: Focusing in prognosis and predictive role of each one
Authors: E.M. Gomez Garcia, N.L. Hernandez-Martinez, L. Lechuga-Becerra, D. Trujillo-Gomez, J. Valdez-Rade
Journal: Annals of Oncology (2022)